Trade Kala Pharma - KALA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.20 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 6.19 |
| Open* | 6.09 |
| 1-Year Change* | 7.98% |
| Day's Range* | 5.97 - 6.17 |
| 52 wk Range | 0.17-2.29 |
| Average Volume (10 days) | 1.21M |
| Average Volume (3 months) | 23.44M |
| Market Cap | 14.64M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 73.21M |
| Revenue | 8.40M |
| EPS | -1.95 |
| Dividend (Yield %) | N/A |
| Beta | 1.14 |
| Next Earnings Date | Nov 14, 2022 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 27, 2023 | 5.98 | -0.11 | -1.81% | 6.09 | 6.17 | 5.97 |
| Nov 24, 2023 | 6.19 | 0.12 | 1.98% | 6.07 | 6.19 | 6.07 |
| Nov 22, 2023 | 6.16 | 0.20 | 3.36% | 5.96 | 6.28 | 5.87 |
| Nov 21, 2023 | 5.94 | 0.12 | 2.06% | 5.82 | 6.02 | 5.72 |
| Nov 20, 2023 | 5.92 | 0.48 | 8.82% | 5.44 | 5.92 | 5.43 |
| Nov 17, 2023 | 5.42 | 0.08 | 1.50% | 5.34 | 5.57 | 5.34 |
| Nov 16, 2023 | 5.21 | -0.04 | -0.76% | 5.25 | 5.32 | 5.19 |
| Nov 15, 2023 | 5.25 | 0.03 | 0.57% | 5.22 | 5.62 | 5.22 |
| Nov 14, 2023 | 5.22 | -0.28 | -5.09% | 5.50 | 6.21 | 5.22 |
| Nov 13, 2023 | 5.27 | -0.10 | -1.86% | 5.37 | 5.47 | 5.23 |
| Nov 10, 2023 | 5.49 | 0.02 | 0.37% | 5.47 | 5.69 | 5.47 |
| Nov 9, 2023 | 5.77 | -0.64 | -9.98% | 6.41 | 6.46 | 5.77 |
| Nov 8, 2023 | 6.46 | -0.12 | -1.82% | 6.58 | 6.58 | 6.27 |
| Nov 7, 2023 | 6.58 | -0.16 | -2.37% | 6.74 | 6.84 | 6.47 |
| Nov 6, 2023 | 6.74 | -0.12 | -1.75% | 6.86 | 6.88 | 6.74 |
| Nov 3, 2023 | 6.91 | 0.20 | 2.98% | 6.71 | 7.16 | 6.65 |
| Nov 2, 2023 | 6.72 | -0.07 | -1.03% | 6.79 | 6.89 | 6.71 |
| Nov 1, 2023 | 6.86 | 0.21 | 3.16% | 6.65 | 6.86 | 6.65 |
| Oct 31, 2023 | 6.76 | -0.13 | -1.89% | 6.89 | 6.93 | 6.65 |
| Oct 30, 2023 | 6.86 | 0.10 | 1.48% | 6.76 | 6.87 | 6.65 |
Kala Pharma Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total revenue | 11.24 | 6.362 | 6.074 | 0 | 0 |
| Revenue | 11.24 | 6.362 | 6.074 | 0 | 0 |
| Total Operating Expense | 145.569 | 102.593 | 94.298 | 65.111 | 39.875 |
| Selling/General/Admin. Expenses, Total | 105.061 | 81.068 | 65.015 | 35.431 | 10.867 |
| Research & Development | 38.132 | 18.352 | 27.275 | 29.29 | 29.008 |
| Operating Income | -134.329 | -96.231 | -88.224 | -65.111 | -39.875 |
| Interest Income (Expense), Net Non-Operating | -8.276 | -8.096 | -6.123 | -1.627 | -2.336 |
| Net Income Before Taxes | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
| Net Income After Taxes | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
| Net Income Before Extra. Items | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
| Net Income | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
| Income Available to Common Excl. Extra. Items | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
| Income Available to Common Incl. Extra. Items | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
| Dilution Adjustment | |||||
| Diluted Net Income | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
| Diluted Weighted Average Shares | 65.2028 | 52.3775 | 34.2098 | 26.7539 | 6.90324 |
| Diluted EPS Excluding Extraordinary Items | -2.1871 | -1.99183 | -2.7579 | -2.49451 | -6.11467 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Diluted Normalized EPS | -2.12446 | -1.99183 | -2.7579 | -2.47994 | -6.11467 |
| Unusual Expense (Income) | 4.084 | 0 | 0.39 | ||
| Cost of Revenue, Total | 4.097 | 3.173 | 2.008 | ||
| Gross Profit | 7.143 | 3.189 | 4.066 | ||
| Other Operating Expenses, Total | -5.805 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total revenue | 1.372 | 1.856 | 3.067 | 3.051 | 3.266 |
| Revenue | 1.372 | 1.856 | 3.067 | 3.051 | 3.266 |
| Cost of Revenue, Total | 0.775 | 1.418 | 0.908 | 1.016 | 0.755 |
| Gross Profit | 0.597 | 0.438 | 2.159 | 2.035 | 2.511 |
| Total Operating Expense | 32.286 | 47.36 | 29.138 | 37.491 | 31.58 |
| Selling/General/Admin. Expenses, Total | 26.982 | 24.027 | 25.349 | 27.986 | 27.699 |
| Research & Development | 4.466 | 29.031 | 2.881 | 3.094 | 3.126 |
| Operating Income | -30.914 | -45.504 | -26.071 | -34.44 | -28.314 |
| Interest Income (Expense), Net Non-Operating | -2.027 | -2.064 | -2.056 | -2.058 | -2.098 |
| Net Income Before Taxes | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
| Net Income After Taxes | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
| Net Income Before Extra. Items | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
| Net Income | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
| Income Available to Common Excl. Extra. Items | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
| Income Available to Common Incl. Extra. Items | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
| Diluted Net Income | -32.941 | -47.568 | -28.127 | -36.498 | -30.412 |
| Diluted Weighted Average Shares | 73.6408 | 69.5132 | 65.0505 | 64.5545 | 61.6559 |
| Diluted EPS Excluding Extraordinary Items | -0.44732 | -0.6843 | -0.43239 | -0.56538 | -0.49325 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.44732 | -0.70316 | -0.43239 | -0.48181 | -0.49325 |
| Unusual Expense (Income) | -1.311 | 0 | 5.395 | ||
| Other Operating Expenses, Total | 0.063 | -5.805 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Current Assets | 124.366 | 171.379 | 105.484 | 177.028 | 115.213 |
| Cash and Short Term Investments | 92.136 | 153.54 | 85.449 | 170.898 | 114.565 |
| Cash | 92.136 | 77.264 | 85.449 | 170.898 | 114.565 |
| Prepaid Expenses | 1.307 | 1.807 | 1.605 | 0.532 | 0.648 |
| Other Current Assets, Total | 4.829 | 0.949 | 0.684 | 0.477 | |
| Total Assets | 139.427 | 221.606 | 154.323 | 220.966 | 116.546 |
| Property/Plant/Equipment, Total - Net | 4.021 | 31.019 | 32.479 | 31.732 | 1.199 |
| Property/Plant/Equipment, Total - Gross | 6.882 | 34.443 | 34.995 | 33.55 | |
| Accumulated Depreciation, Total | -2.861 | -3.424 | -2.516 | -1.818 | |
| Other Long Term Assets, Total | 11.04 | 19.208 | 16.36 | 12.206 | 0.134 |
| Total Current Liabilities | 37.422 | 22.225 | 24.774 | 17.01 | 14.872 |
| Accounts Payable | 4.899 | 1.724 | 2.518 | 5.446 | 1.202 |
| Accrued Expenses | 21.697 | 20.501 | 22.256 | 11.564 | 7.003 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 6.667 | |||
| Total Liabilities | 122.623 | 121.611 | 124.631 | 115.988 | 26.867 |
| Total Long Term Debt | 78.929 | 72.243 | 71.184 | 70.226 | 11.987 |
| Long Term Debt | 78.929 | 72.243 | 71.184 | 70.226 | 11.987 |
| Other Liabilities, Total | 6.272 | 27.143 | 28.673 | 28.752 | 0.008 |
| Total Equity | 16.804 | 99.995 | 29.692 | 104.978 | 89.679 |
| Redeemable Preferred Stock | 0 | 0 | |||
| Common Stock | 0.066 | 0.059 | 0.036 | 0.034 | 0.025 |
| Additional Paid-In Capital | 559.126 | 499.715 | 325.112 | 306.053 | 224.025 |
| Retained Earnings (Accumulated Deficit) | -542.388 | -399.783 | -295.456 | -201.109 | -134.371 |
| Total Liabilities & Shareholders’ Equity | 139.427 | 221.606 | 154.323 | 220.966 | 116.546 |
| Total Common Shares Outstanding | 65.5003 | 58.9154 | 36.0863 | 33.8631 | 24.5383 |
| Total Receivables, Net | 17.455 | 9.854 | 13.098 | 1.026 | |
| Total Inventory | 8.639 | 5.229 | 4.648 | 4.095 | |
| Accounts Receivable - Trade, Net | 15.345 | 9.604 | 11.563 | ||
| Short Term Investments | 0 | 76.276 | |||
| Other Equity, Total | 0 | 0.004 | |||
| Other Current Liabilities, Total | 10.826 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 98.255 | 124.366 | 149.086 | 171.72 | 179.065 |
| Cash and Short Term Investments | 70.162 | 92.136 | 124.503 | 149.635 | 155.985 |
| Cash | 65.17 | 92.136 | 124.503 | 144.635 | 127.97 |
| Short Term Investments | 4.992 | 0 | 0 | 5 | 28.015 |
| Total Receivables, Net | 13.02 | 15.345 | 12.63 | 11.859 | 12.206 |
| Accounts Receivable - Trade, Net | 13.02 | 15.345 | 12.63 | 11.859 | 12.206 |
| Total Inventory | 10.531 | 8.639 | 7.708 | 8.046 | 8.241 |
| Prepaid Expenses | 4.542 | 5.293 | 4.245 | 2.18 | 2.633 |
| Total Assets | 111.574 | 139.427 | 193.814 | 215.464 | 229.827 |
| Property/Plant/Equipment, Total - Net | 4.089 | 4.021 | 30.481 | 31.369 | 31.584 |
| Other Long Term Assets, Total | 9.23 | 11.04 | 14.247 | 12.375 | 19.178 |
| Total Current Liabilities | 32.758 | 37.422 | 27.195 | 26.076 | 19.989 |
| Accounts Payable | 6.218 | 4.899 | 5.845 | 2.844 | 2.855 |
| Accrued Expenses | 21.864 | 21.697 | 21.35 | 23.232 | 17.134 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 116.858 | 122.623 | 132.345 | 131.194 | 120.035 |
| Total Long Term Debt | 79.361 | 78.929 | 78.491 | 78.055 | 72.521 |
| Long Term Debt | 79.361 | 78.929 | 78.491 | 78.055 | 72.521 |
| Other Liabilities, Total | 4.739 | 6.272 | 26.659 | 27.063 | 27.525 |
| Total Equity | -5.284 | 16.804 | 61.469 | 84.27 | 109.792 |
| Common Stock | 0.073 | 0.066 | 0.065 | 0.065 | 0.064 |
| Additional Paid-In Capital | 569.974 | 559.126 | 556.224 | 550.898 | 539.92 |
| Retained Earnings (Accumulated Deficit) | -575.329 | -542.388 | -494.82 | -466.693 | -430.195 |
| Other Equity, Total | -0.002 | 0 | 0 | 0 | 0.003 |
| Total Liabilities & Shareholders’ Equity | 111.574 | 139.427 | 193.814 | 215.464 | 229.827 |
| Total Common Shares Outstanding | 72.594 | 65.5003 | 65.0852 | 64.7702 | 63.8051 |
| Other Current Assets, Total | 2.953 | ||||
| Accumulated Depreciation, Total | -2.861 | ||||
| Other Current Liabilities, Total | 4.676 | 10.826 |
- Annual
- Quarterly
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -142.605 | -104.327 | -94.347 | -66.738 | -42.211 |
| Cash From Operating Activities | -108.235 | -90.694 | -92.72 | -54.121 | -34.098 |
| Cash From Operating Activities | 0.975 | 0.912 | 0.843 | 0.352 | 0.287 |
| Non-Cash Items | 44.011 | 16.294 | 12.722 | 9.882 | 5.526 |
| Cash Interest Paid | 6.837 | 7.528 | 7.522 | 3.041 | 0.863 |
| Changes in Working Capital | -10.616 | -3.573 | -11.938 | 2.383 | 2.3 |
| Cash From Investing Activities | 70.803 | -78.209 | -1.335 | -1.578 | -0.48 |
| Capital Expenditures | -0.886 | -1.942 | -1.335 | -1.578 | -0.48 |
| Cash From Financing Activities | 42.554 | 160.628 | 8.982 | 124.104 | 103.696 |
| Financing Cash Flow Items | -2.25 | ||||
| Issuance (Retirement) of Stock, Net | 42.817 | 160.66 | 9.012 | 71.296 | 97.057 |
| Issuance (Retirement) of Debt, Net | -0.263 | -0.032 | -0.03 | 52.808 | 8.889 |
| Net Change in Cash | 5.122 | -8.275 | -85.073 | 68.405 | 69.118 |
| Other Investing Cash Flow Items, Total | 71.689 | -76.267 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -32.941 | -142.605 | -95.037 | -66.91 | -30.412 |
| Cash From Operating Activities | -24.089 | -108.235 | -80.331 | -54.248 | -32.64 |
| Cash From Operating Activities | 0.157 | 0.975 | 0.763 | 0.504 | 0.248 |
| Non-Cash Items | 3.479 | 44.011 | 21.534 | 16.592 | 5.519 |
| Cash Interest Paid | 1.603 | 6.837 | 5.2 | 3.03 | 1.851 |
| Changes in Working Capital | 5.216 | -10.616 | -7.591 | -4.434 | -7.995 |
| Cash From Investing Activities | -5.073 | 70.803 | 75.426 | 70.705 | 48.031 |
| Capital Expenditures | -0.081 | -0.886 | -0.874 | -0.545 | -0.219 |
| Other Investing Cash Flow Items, Total | -4.992 | 71.689 | 76.3 | 71.25 | 48.25 |
| Cash From Financing Activities | 0.154 | 42.554 | 42.394 | 41.164 | 35.315 |
| Issuance (Retirement) of Stock, Net | 0.163 | 42.817 | 42.648 | 41.409 | 35.324 |
| Issuance (Retirement) of Debt, Net | -0.009 | -0.263 | -0.254 | -0.245 | -0.009 |
| Net Change in Cash | -29.008 | 5.122 | 37.489 | 57.621 | 50.706 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Kala Pharma Company profile
About Kala Pharmaceuticals Inc
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for diseases of the eye. The Company's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, is a short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. INVELTYS (loteprednol etabonate ophthalmic suspension) 1%, is a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. The Company's AMPPLIFY technology uses selectively-sized nanoparticles that each have a proprietary coating. Its Preclinical Development Programs include rTKI Program for Retinal Diseases (KPI-285/KPI-286), SEGRM Program and Surface Targeted Steroid Program (KPI-333).
Financial summary
BRIEF: For the nine months ended 30 September 2021, Kala Pharmaceuticals Inc revenues increased from $4.1M to $9.4M. Net loss increased 30% to $95M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 48% to $70.6M (expense), Stock-Based Compensation increase of 50% to $10.4M (expense).
| Industry: | Pharmaceuticals (NEC) |
1167 Massachusetts Avenue
02476
Income Statement
- Annual
- Quarterly
News
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023
XAU/USD Latest: Gold advances as weaker data weighs on US yields
Gold moves higher as softer economic data weighs on US yields and the dollar
13:43, 17 November 2023
Crude prices extend tumble as demand fears loom ahead of next OPEC+ meeting
Crude has extended its sell-off as demand risks loom ahead of OPEC+’s meeting on November 26. We look at the drivers of oil prices and the key technical levels of WTI Crude.
13:07, 17 November 2023
AUD/USD Retests Key Resistance Zone
The US dollar weakened notably following the latest CPI data, showing a larger-than-expected dip to 3.2% in October. This decline, the first in four months, sparked a surge in AUD/USD on Tuesday, pushing prices back into a crucial resistance zone established since August (see daily candle chart below).
10:24, 17 November 2023
Strategy Smarts Part 2: Trading Trend Days
Welcome to our four-part Strategy Smarts series designed to give you some practical trading templates which build on the concepts outlined in our Day Traders Toolbox and Power Patterns series. Today’s piece centres around Trend Days; what they are, how to spot them early and most importantly, how to trade them consistently.
10:18, 15 November 2023
Apple Regain Bullish Momentum
Apple's share price has rallied since the release of their recent financial results on 2nd November, despite certain concerns over growth in China.
10:17, 14 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com